De‐simplifying antiretroviral therapy from a single‐tablet to a two‐tablet regimen: Acceptance, patient‐reported outcomes, and cost savings in a multicentre study.

Autor:	Oosterhof, P., de Zoete, B. G. J. A., Vanhommerig, J. W., Langebeek, N., Gisolf, E. H., van Hulzen, A. G. W., Lammers, A. J. J., Weijsenfeld, A. M., van der Valk, M., Grintjes, K., van Crevel, R., van Luin, M., Brinkman, K., Burger, D. M.
Předmět:	PATIENT compliance COST control ANTIRETROVIRAL agents QUESTIONNAIRES HIV-positive persons HIV infections DESCRIPTIVE statistics EFAVIRENZ-emtricitabine-tenofovir (Drug) LONGITUDINAL method DRUG tablets RESEARCH QUALITY of life DRUGS HEALTH outcome assessment CLINICS PATIENT satisfaction PATIENTS' attitudes TIME
Zdroj:	HIV Medicine; Sep2024, Vol. 25 Issue 9, p1019-1029, 11p
Abstrakt:	Background: Antiretroviral therapy (ART), which is increasingly used by people with HIV, accounts for significant care costs, particularly because of single‐tablet regimens (STRs). This study explored de‐simplification to a two‐tablet regimen (TTR) for cost reduction. The objectives of this study were: (1) acceptance of de‐simplification, (2) patient‐reported outcomes, and (3) cost savings. Methods: All individuals on Triumeq®, Atripla® or Eviplera® in five HIV clinics in the Netherlands were eligible. Healthcare providers informed individuals of this study. After inclusion, individuals were free to de‐simplify. An electronic questionnaire was sent to assess study acceptance, adherence, quality of life (SF12) and treatment satisfaction (HIVTSQ). After 3 and 12 months, questionnaires were repeated. Cost savings were calculated using Dutch drug prices. Results: In total, 283 individuals were included, of whom 55.5% agreed to de‐simplify their ART, with a large variability between treatment centres: 41.1–74.2%. Individuals who were willing to de‐simplify tended to be older, had a longer history of HIV diagnosis, and used more co‐medication than those who preferred to remain on an STR regimen. Patient‐reported outcomes, including quality of life and treatment satisfaction, showed no significant difference between people with HIV who switched to a TTR and those who remained on an STR regimen. Furthermore, we observed a 17.8% reduction in drug costs in our cohort of people with HIV who were initially on an STR. Conclusions: De‐simplification from an STR to a TTR within the Dutch healthcare setting has been demonstrated as feasible, leads to significant cost reductions and should be discussed with every eligible person with HIV in the Netherlands. [ABSTRACT FROM AUTHOR]
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu Plný text